Sales performance of Chimeric Antigen Receptor (CAR)-T Cell therapies has been interchanging. Novartis' Kymriah, which entered the market first, is troubling as latecomer competitors enter the market. In contrast, sales of Jansen's Carvykti and BMS' Breyanzi expanded significantly due to expanded indications.

According to the pharmaceutical industry on December 3, Carvykti generated sales of US$286 million (about KRW 40 billion) in Q3, up 88% YoY. Carvykti recorded US$629 million in net sales for 9 months this year, up 84% from US$341 million last year.

CAR-T is a gene and cell therapy, which involves engineering T-cells to express receptors responding to particular types of cancer cells. Th